Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma

Journal of Immunotherapy

Volumn 37, Issue 9, 2014, Pages 448-460

  Forget, Marie Andrée ^a,b   Malu, Shruti ^a   Liu, Hui ^c   Toth, Christopher ^a   Maiti, Sourindra ^b   Kale, Charuta ^a   Haymaker, Cara ^a   Bernatchez, Chantale ^a   Huls, Helen ^b   Wang, Ena ^c,e   Marincola, Francesco M ^e   Hwu, Patrick ^a   Cooper, Laurence J N ^b   Radvanyi, Laszlo G ^a,d  

^a Department of Melanoma Medical Oncology ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d Lion Biotechnologies   (United States)

^e SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

Author keywords

Adoptive T cell therapy; Artificial antigen presenting cells; Costimulation; K562; Melanoma; Tumor infiltrating lymphocytes

Indexed keywords

CD137 LIGAND; CD86 ANTIGEN; INTERLEUKIN 15; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ARTICLE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL EXPANSION; CELL GROWTH; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; IMMUNOLOGY; K562 CELL LINE; SKIN TUMOR;

ANTIGEN-PRESENTING CELLS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; SKIN NEOPLASMS; TRANSCRIPTOME;

EID: 84916597538     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000056     Document Type: Article

References (48)

1. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-2357.
2. Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of shortterm cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16:2646-2655.
3. Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18: 6758-6770.
4. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550-4557.
5. Itzhaki O, Hovav E, Ziporen Y, et al. Establishment and largescale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011;34:212-220.
6. Pilon-Thomas S, Kuhn L, Ellwanger S, et al. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012;35:615-620.
7. Riddell SR, Watanabe KS, Goodrich JM, et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257:238-241.
8. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003; 3:666-675.
9. Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26:332-342.
10. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45:321-334.
11. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD2 and 4-1BB. Nat Biotechnol. 2002;20:143-148.
12. Denis-Mize KS, Dupuis M, MacKichan ML, et al. Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther. 2000;7:2105-2112.
13. Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516-3527.
14. Butler MO, Lee JS, Ansen S, et al. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007; 13:1857-1867.
15. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/ transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427-437.
16. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33:305-315.
17. Li Y, Liu S, Hernandez J, et al. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol. 2010;184:452-465.
18. Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961-2971.
19. Zhang M, Maiti S, Bernatchez C, et al. A new approach to simultaneously quantify both TCR alpha-and beta-chain diversity after adoptive immunotherapy. Clin Cancer Res. 2012;18:4733-4742.
20. He L, Hakimi J, Salha D, et al. A sensitive flow cytometrybased cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods. 2005; 304:43-59.
21. Romero P, Zippelius A, Kurth I, et al. Four functionnally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol. 2007;178:4112-4119.
22. Satoh M, Seki S, Hashimoto W, et al. Cytotoxic gammadelta or alphabeta T cells with a natural killer cell marker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2. J Immunol. 1996;157: 3886-3892.
23. Pittet MJ, Speiser DE, Valmori D, et al. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol. 2000; 164:1148-1152.
24. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30:899-911.
25. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110:2983-2990.
26. Kaldjian EP, Gretz JE, Anderson AO, et al. Spatial and molecular organization of lymph node T cell cortex: a labyrinthine cavity bounded by an epithelium-like monolayer of fibroblastic reticular cells anchored to basement membranelike extracellular matrix. Int Immunol. 2001;13:1243-1253.
27. Shannon LA, Calloway PA, Welch TP, et al. CCR7/CCL2 migration on fibronectin is mediated by phospholipase Cgamma1 and ERK1/2 in primary T lymphocytes. J Biol Chem. 2010;285:38781-38787.
28. Kvistborg P, Shu CJ, Heemskerk B, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients. Oncoimmunology. 2012;1:409-418.
29. Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747-752.
30. Jin J, Sabatino M, Somerville R, et al. Simplified method of the growth of human tumor infiltrating lymphocytes in gaspermeable flasks to numbers needed for patient treatment. J Immunother. 2012;35:283-292.
31. Ye Q, Loisiou M, Levine BL, et al. Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Trans Med. 2011;9:131-143.
32. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med. 1997;186:47-55.
33. Friedman KM, Devillier LE, Feldman SA, et al. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother. 2011;34: 651-661.
34. Chacon JA, Wu RC, Sukhumalchandra P, et al. Costimulation through 4-1BB/CD137 improves the expansion and function of CD8+ melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013;8:e60031.
35. Zhu BQ, Ju SW, Shu YQ. CD137 enhances cytotoxicity of CD3+CD56+ cells and their capacities to induce CD4+ Th responses. Biomed Pharmacother. 2009;63:509-516.
36. Hernandez-Chacon JA, Li Y, Wu RC, et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J Immunother. 2011;34:236-250.
37. Franceschetti M, Pievani A, Borleri G, et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol. 2009;37:616-628, e612.
38. Legat A, Speiser DE, Pircher H, et al. Inhibitory receptor expression depends more dominantly on differentiation and activation than "exhaustion" of human CD8 T cells. Front Immunol. 2013;4:455-469.
39. Chapuis AG, Thompson JA, Margolin KA, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA. 2012;109:4592-4597.
40. Lee DY, Choi BK, Lee DG, et al. 4-1BB signaling activates the T cell factor 1 effector/beta-catenin pathway with delayed kinetics via ERK signaling and delayed PI3K/AKT activation to promote the proliferation of CD8+ T cells. PLoS One. 2013;8:e69677.
41. Kermani H, Goffinet L, Mottet M, et al. Expression of the growth hormone/insulin-like growth factor axis during Balb/c thymus ontogeny and effects of growth hormone upon ex vivo T cell differentiation. Neuroimmunomodulation. 2012;19:137-147.
42. Ni F, Sun R, Fu B, et al. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun. 2013; 4:1479-1489.
43. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-7311.
44. Dannenmann SR, Thielicke J, Stockli M, et al. Tumorassociated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. Oncoimmunology. 2013;2:e23562.
45. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645-2652.
46. Wagner C, Burger A, Radsak M, et al. Fibronectin synthesis by activated T lymphocytes: up-regulation of a surfaceassociated isoform with signalling function. Immunology. 2000;99:532-539.
47. Blum S, Hug F, Hansch GM, et al. Fibronectin on activated T lymphocytes is bound to gangliosides and is present in detergent insoluble microdomains. Immunol Cell Biol. 2005; 83:167-174.
48. Andersen RS, Thrue CA, Junker N, et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 2012; 72:1642-1650.